UNDERWRITING AGREEMENTUnderwriting Agreement • February 12th, 2018 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 12th, 2018 Company Industry JurisdictionGemphire Therapeutics Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,142,858 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 471,429 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”